The following drugs show a genetic alteration in ACC that may respond to therapy (Supplementary Table S6): MDM2 inhibitors and p53 reactivators APG-115 and BI 907828 (currently tested in clinical studies) showed a predicted response in 26% of tumors. This evidence concerns the gene MDM2 and adrenal cortex carcinoma.